Hansaitai Biopharmaceutical Technology (Wuhan) Co Ltd 2025 Sustainability Report
Company: Hansaitai Biopharmaceutical Technology (Wuhan) Co Ltd
Sector: Manufacturing
Country: China
Year: 2025
Type: Sustainability Report
Pages: 41
The report presents the Group's 2025 ESG performance, including Scope 2 and Scope 3 emissions, resource consumption, Board-level ESG oversight and a US$100,000 community donation after a Hong Kong fire disaster.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.